Mark Reynolds
Psychiatry · Durham, NCNPI 1023052503
Payments from drug & device makers
Across 3,172 payments — averaging $1002.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$720K
- Alkermes, Inc.$671K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$602K
- Johnson & Johnson$601K
- Teva Pharmaceuticals USA, Inc.$308K
- E.r. Squibb & Sons, L.L.C.$274K
- plus $3K from 6 others
What the payments were for
- Consulting fees$118,2934%
- Speaking & faculty fees$2,672,27684%
- Travel & lodging$328,47610%
- Food & beverage$59,4842%
- Education$1690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 655 | $720,002 |
| Alkermes, Inc. | 800 | $671,096 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 568 | $601,704 |
| Johnson & Johnson | 584 | $601,243 |
| Teva Pharmaceuticals USA, Inc. | 284 | $307,724 |
| E.r. Squibb & Sons, L.L.C. | 204 | $273,921 |
| Sunovion Pharmaceuticals Inc. | 23 | $1,242 |
| Otsuka America Pharmaceutical, Inc. | 15 | $1,002 |
| Lundbeck LLC | 29 | $597 |
| Indivior Inc. | 7 | $108 |
| AbbVie | 2 | $31 |
| USWM, LLC | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$2,168,754
- INGREZZA$711,124
- CAPLYTA$594,532
- INVEGA SUSTENNA$593,926
- INVEGA TRINZA$587,530
- ARISTADA INITIO$533,200
- LYBALVI$485,951
- UZEDY$304,649
- COBENFY$213,939
- INVEGA$1,515
- LATUDA$700
- ABILIFY MAINTENA$559
- ABILIFY ASIMTUFII$317
- REXULTI$125
- AUSTEDO$114
- SPRAVATO$113
How this compares
$3,178,698 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 210 | $727,980 |
| IngrezzaValbenazine Tosylate | 39 | $305,765 |
| AristadaAripiprazole Lauroxil | 77 | $244,841 |
| Abilify MaintenaAripiprazole | 84 | $242,059 |
| CaplytaLumateperone Tosylate | 95 | $141,809 |
| UzedyRisperidone | 23 | $121,940 |
| Abilify AsimtufiiAripiprazole | 13 | $72,414 |
| LybalviOlanzapine/Samidorphan Malate | 36 | $55,105 |
| RexultiBrexpiprazole | 25 | $35,614 |
| VivitrolNaltrexone Microspheres | 16 | $27,458 |
| TrintellixVortioxetine Hydrobromide | 47 | $22,221 |
| Paliperidone ErPaliperidone | 81 | $9,642 |
| Fluphenazine Decanoate | 40 | $6,120 |
| Clozapine | 48 | $4,588 |
| Olanzapine | 101 | $2,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $601,243 | $727,980210 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii, Rexulti | $1,002 | $350,087122 claims |
| Alkermes, Inc.Aristada, Lybalvi, Vivitrol | $671,096 | $327,404129 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $720,002 | $305,76539 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $601,704 | $141,80995 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $307,724 | $121,94023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Durham
- Dan BlazerDurham$1M
- Andrew KrystalDurham$754K
- Rachel DewDurham$520K
- Steven SzaboDurham$412K
- Ranjan SudanDurham$303K
- Mustafa HusainDurham$156K
- Paolo MannelliDurham$98K
- Mark ChandlerDurham$86K
- Caleb WhitenackDurham$68K
- P DoraiswamyDurham$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.